Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 5/20 | 0.51 |
| ▸ | CRBN | Q96SW2 | 9/20 | 0.49 |
| ▸ | DDB1 | Q16531 | 8/20 | 0.49 |
| ▸ | IL1B | P01584 | 3/20 | 0.42 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.42 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29348558 | 0.84 | CNR2 (0.53) | CRBNDDB1 | |
| SCHEMBL31068239 | 0.83 | DDB1 (0.43) | TNFCRBNDDB1IKZF3 | |
| SCHEMBL29348524 | 0.82 | CRBN (0.44) | TNFCRBNDDB1IL1BIKZF3 | |
| SCHEMBL29348387 | 0.81 | DDB1 (0.46) | TNFCRBNDDB1IL1BIKZF3 | |
| SCHEMBL31068261 | 0.81 | DDB1 (0.47) | CRBNDDB1 | |
| SCHEMBL29348711 | 0.81 | DDB1 (0.47) | CRBNDDB1 | |
| SCHEMBL29348445 | 0.80 | DDB1 (0.41) | TNFCRBNDDB1IL1BIKZF3 | |
| SCHEMBL29348409 | 0.80 | DDB1 (0.41) | TNFCRBNDDB1IKZF3 | |
| SCHEMBL31068095 | 0.80 | CRBN (0.46) | CRBNDDB1IKZF3 | |
| SCHEMBL29348712 | 0.80 | CRBN (0.46) | CRBNDDB1IKZF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151547-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |